



PATENT

Attorney Docket No.: 34471/US/3/RFT/SKS

Attorney File No.: 459258-00014

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gallop

Serial No.: 10/734,631

Filing Date: December 11, 2003

For: Orally Administered Dosage Forms

of Fused GABA Analog Prodrugs

Having Reduced Toxicity

Examiner:

Not Yet Assigned

Art Unit:

1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Anril 1, 2005

Signed

Judi Stillwel

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1287 Off. Gaz. Pat. Office 163, 10/19/2004, no copies of U.S. patents and U.S. published applications are enclosed. Copies of these references are enclosed.

None of the foregoing references are believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

Serial No. 10/742,631

Filing Date: December 11, 2003

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no additional fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 459258-00014 [34471/US/3/RFT/SKS]).

By:

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: April 1, 2005

Customer Number: 32940 Dorsey & Whitney LLP

Intellectual Property Department Four Embarcadero Center, Suite 3400

San Francisco, CA 94111-4187 Telephone: (415) 781-1989 Facsimile: (415) 398-3249

Attachments: Form PTO/SB/8A, Substitute for form 1449

4 cited references Return Postcard 0 4 2005

Sheet

Substitute for form 1449A/PTO (Modified)

INFORMATION DISCLOSURE THADENSTATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known
Application Number	10/734,631
Filing Date	December 11, 2003
First Named Inventor	Gallop
Art Unit	1614
Examiner Name	Not assigned
Attorney Docket Number	34471/US/3

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,285,987	08-21-1981	Ayer et al.	
	Δ2	6 833 140	12-21-2004	Cundy et al.	

1

		FC	REIGN PATENT	T DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (<i>if</i> known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1					

	NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	<u> </u>	LINHARDT, "Biodegradable Polymers for Controlled Release of Drugs," Chapter 2 of Controlled	
	C1	Release of Drugs, Rosoff (Ed.), pp. 53-95, VCH Publishers, 1989	
	-	HOES et al., "The Application of Drug-Polymer Conjugates in ChemoTherapy," Chapter 3 of	-
	C2	Drug Carrier Systems, Roerdink and Kroons (Ed.) pp. 57-109, John Wiley & Sons Ltd, 1989	

Examiner	Date Considered
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

16 if possible. Applicant is to place a cneck mark nere if English Language I ranslation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.